1. Gerhardt F, Fiessler E, Olsson KM, Kayser MZ, Kovacs G, Gall H et al. Positive vasoreactivity testing in pulmonary arterial hypertension: therapeutic consequences, treatment patterns, and outcomes in the modern management era. Circulation. 2024;149(20):1549–1564. doi:10.1161/CIRCULATIONAHA.122.063821
2. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. New Engl J Med. 1992;327(2):76–81. doi:10.1056/NEJM199207093270203
3. Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, De Marco T et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry. J Am Heart Assoc. 2022;11(9):e024969. doi:10.1161/JAHA.121.024969
4. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53(1):1801900. doi:10.1183/13993003.01900-2018
5. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
6. Montani D, Savale L, Natali D, Jaïs X, Herve P, Garcia G et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898–1907. doi:10.1093/eurheartj/ehq170
7. Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation. 1996;93(3):484–488. doi:10.1161/01.cir.93.3.484
8. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111(23):3105–3111. doi:10.1161/CIRCULATIONAHA.104.488486
9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317
10. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am College Cardiol. 2006;47(4):799–803. doi:10.1016/j.jacc.2005.09.054
11. Naranjo M, Rosenzweig EB, Hemnes AR, Jacob M, Desai A, Hill NS et al. Frequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: results from the pulmonary vascular disease phenomics study. Pulm Circ. 2023;13(3): e12281. doi:10.1002/pul2.12281
12. Chin KM, Gaine SP, Gerges C, Jing ZC, Mathai SC, Tamura Y et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325. doi:10.1183/13993003.01325-2024
13. Chandrasekara S, Lau EM, Anderson J, Collins N, Cordina R, Corrigan C et al. Acute vasoreactivity testing and outcomes in pulmonary arterial hypertension: a call for increased testing. Heart Lung Circ. 2023;32(2):156–165. doi:10.1016/j.hlc.2022.09.005
14. Sharma A, Obiagwu C, Mezue K, Garg A, Mukherjee D, Haythe J et al. Role of vasodilator testing in pulmonary hypertension. Prog Cardiovasc Dis. 2016;58(4):425–433. doi:10.1016/j.pcad.2015.09.006
15. Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulm Circ. 2017;7(3):588–597. doi:10.1177/2045893217714231
16. Xiao L, Tong X. Advances in molecular mechanism of vascular remodeling in pulmonary arterial hypertension. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2019;48(1):102–110. doi:10.3785/j.issn.1008-9292.2019.02.15
17. Morrell NW, Adnot S, Archer SL, Dupuis J, Lloyd Jones P, MacLean MR et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S20–S31. doi:10.1016/j.jacc.2009.04.018
18. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53(1):1801900. doi:10.1183/13993003.01900-2018
19. Гончарова Н. С., Лапшин К. Б., Матакаева Ж. А., Андреева Е. М., Моисеева О. М. Клиническое значение вазореактивности у пациентов с легочной артериальной гипертензией: новый взгляд на хорошо забытое. Артериальная гипертензия. 2024;30(2):174–184. doi:10.18705/1607-419X-2024-2380
20. Langleben D, Orfanos S. Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulm Circ. 2017;7(3):588–597. doi:10.1177/2045893217714231
21. Hirakawa K, Asano R, Ueda J, Aoki T, Tsuji A, Ogo T. Calcium channel blockers in patients with pulmonary arterial hypertension receiving PAH-specific treatment. Int J Cardiol. 2024;406:132043. doi:10.1016/j.ijcard.2024.132043
22. Goncharova N, Lapshin K, Berezina A, Zlobina I, Ryzkhov A, Matakaeva Z et al. Vasoreactive testing prevalence and characteristics in patients with idiopathic pulmonary arterial hypertension. Annals of Thoracic Medicine 2025;20(1):62–70. doi:10.4103/atm.atm_189_24
